**Name of Journal: *World Journal of Methodology***

**Manuscript NO: 33887**

**Manuscript Type: Review**

**Shortness of breath in clinical practice: A case for left atrial function and exercise stress testing for a comprehensive diastolic heart failure workup**

Iyngkaran P *et al.* Diastolic heart failure workup

**Pupalan Iyngkaran, Nagesh S Anavekar, Christopher Neil, Liza Thomas, David L Hare**

**Pupalan Iyngkaran,** Department of Medicine, Northern Territory Medical School, Flinders University, Charles Darwin Universitycampus, Casuarina NT 0815, Australia

**Nagesh S Anavekar**, Department of Cardiology, Northern Hospital, Northern Health, University of Melbourne, Melbourne, VIC 3076, Australia

**Christopher Neil,** Cardiology Unit Western Health, Department of Medicine, Western Precinct, University of Melbourne, Melbourne, VIC 3076, Australia

**Liza Thomas,** South Western Sydney Clinical School, University of New South Wales, Sydney, NSW 2145 Australia

**Liza Thomas,** Westmead Hospital, Westmead Clincal School, University of Sydney, NSW 2145, Australia

**David L Hare,** Cardiovascular Research, University of Melbourne, Melbourne, VIC 3076, Australia

**David L Hare,** Heart Failure Services, Austin Health, Melbourne, VIC 3084, Australia

**Author contributions:** Iyngkaran P wrote the paper; all authors read, agreed on arguments raised and provided feedback on paper.

**Conflict-of-interest statement:** All co-authors have secured independent and governmental research funding. None pose a conflict of interest for this review.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to:** **Pupalan Iyngkaran, FRACP, MBBS, MD,** Department of Medicine, Northern Territory Medical School, Flinders University, Charles Darwin Universitycampus, Yellow Building 4 Cnr University Drive North and University Drive West, Casuarina NT 0815, Australia. pupalan.iyngkaran@flinders.edu.au

**Telephone:** +61-03-97487377

**Fax:** +61-03-97487388

**Received:** March 10, 2017

**Peer-review started:** March 17, 2017

**First decision:** May 23, 2017

**Revised:** June 29, 2017

**Accepted:** November 22, 2017

**Article in press:**

**Published online:**

**Abstract**

The symptom cluster of shortness of breath (SOB) contributes significantly to the outpatient workload of cardiology services. The workup of these patients includes blood chemistry and biomarkers, imaging and functional testing of the heart and lungs. A diagnosis of diastolic heart failure is inferred through the exclusion of systolic abnormalities, a normal pulmonary function test and normal hemoglobin, coupled with diastolic abnormalities on echocardiography. Differentiating confounders such as obesity or deconditioning in a patient with diastolic abnormalities is difficult. While the most recent guidelines provide more avenues for diagnosis, such as incorporating the left atrial size, little emphasis is given to understanding left atrial function, which contributes to at least 25% of diastolic left ventricular filling; additionally, exercise stress testing to elicit symptoms and test the dynamics of diastolic parameters, especially when access to the ‘gold standard’ invasive tests is lacking, presents clinical translational gaps. It is thus important in diastolic heart failure work up to understand left atrial mechanics and the role of exercise testing to build a comprehensive argument for the diagnosis of diastolic heart failure in a patient presenting with SOB.

**Key words:** Diastolic heart failure; Exercise stress test; Left atrium; Shortness of breath; Work-up

**© The Author(s) 2017.** Published by Baishideng Publishing Group Inc. All rights reserved.

**Core tip:** Shortness of breath is a common clinical complaint. Etiologies such as systolic heart failure, obstructive airways disease or anemia have clear and reproducible physiological changes detectable through routine diagnostic tests. Diastolic heart failure (DHF) is often a diagnosis of exclusion. In the absence of directly demonstrating an elevation of left ventricular end diastolic pressures at rest or exercise, DHF is inferred by a combination of symptoms and resting echocardiography findings. We discuss the importance of a wider consideration, *e.g.*, left atrium function and exercise stress testing, in DHF work-up.

Iyngkaran P, Anavekar NS, Neil C, Thomas L, Hare DL. Shortness of breath in clinical practice: A case for left atrial function and exercise stress testing for a comprehensive diastolic heart failure workup. *World J Methodol* 2017; In press

**INTRODUCTION**

Most cardiological services are faced with a large number of referrals to diagnose and manage the symptom cluster of dyspnea or shortness of breath (SOB). Broadly the etiologies can be cardiac, respiratory, haematological, due to obesity or physical deconditioning. When a cardiac cause is considered likely, imaging modalities such as echocardiography and occasionally cardiac magnetic resonance imaging can rule out systolic heart failure or heart failure with reduced ejection fraction (SHF/HFrEF). Diastolic heart failure or heart failure with preserved ejection fraction (DHF/HFpEF) can be inferred, but requires greater analysis. Exercise stress protocols are also receiving greater attention for diagnosis of HFpEF.

To understand the controversies in DHF it is important to go back to the basics. HF is defined as “a clinical syndrome characterized by typical symptoms (*e.g.,* breathlessness, ankle swelling and fatigue) that may be accompanied by signs (*e.g.,* elevated jugular venous pressure, pulmonary crackles and peripheral oedema) caused by a structural and/or functional cardiac abnormality, resulting in a reduced cardiac output and/or elevated intracardiac pressures at rest or during stress”[1]. From this, four points are important in the work-up of patients suspected with DHF syndrome: (1) chronic functional SOB, is the main reason for seeking medical care, however asymptomatic structural changes can also be detected. The correlation of changes at rest and with exercise with or without symptoms are yet to be adequately clarified; (2) in presentations with acute SOB admissions, risk stratifying diastolic abnormalities to a clinical course is also problematic[2,3]; for example are the observed changes age related or evidence of diastolic dysfunction contributing to DHF; (3) three conditions must be satisfied to rule in the diagnosis of HFpEF: Clinical symptoms of heart failure; normal or mildly abnormal systolic function (left ventricular ejection fraction (LVEF) > 50%); and demonstration of diastolic abnormalities in left ventricular (LV) relaxation and filling, and stiffness manifesting as increased LV filling pressures (invasively measured as LV end diastolic pressure > 16 mmHg (LVEDP) or mean pulmonary capillary wedge pressure or mean left atrial (LA) pressure >12 mmHg), at rest or with exercise[2,4]; and (4) demonstrating altered LV pathophysiology in the “resting state” are better established, while evaluation of dynamic diastolic changes (*i.e.,* during exercise) and alterations in left atrium (LA) metrics (*i.e.,* volume or function parameters), have not be given enough emphasis.

The incidence of HFpEF appears to be increasing relative to HFrEF. Combined data among HF presentations reveals an average prevalence of 54% (range 40%-71%)[5]. The etiology and pathophysiological basis also appears different. Patients tend to be older with greater burden of co-morbidities[6,7]. Cardiovascular and non-cardiovascular mortality is increased, although lower than HFrEF. However, survival trends are improving with HFrEF but not HFpEF[8-11]. There have been numerous publications and guideline updates that provide a synopsis of pathophysiology[12-14], clinical correlation and pathways for assessment of DHF[1-3,15] and management[16]. This review is focused on establishing the importance of LA function and exercise testing in the workup of a patient presenting with SOB. We also explore the rationale for including LA metrics under the umbrella of the DHF syndrome focusing on published work using echocardiography as the imaging modality (DHF and HFpEF are used interchangeably, where DHF is used in context of the syndrome and HFpEF in the scientific commentary).

**LEFT ATRIAL ANATOMY, PHYSIOLOGY AND FUNCTION IN HEALTH AND DISEASE**

The LA is predominately composed of overlapping and varyingly aligned layers of muscle fibers that have marked variation in thickness but is overall, significantly thinner than the LV. The left coronary artery and oblique vein, which drain into the coronary sinus, are the main arterial and venous blood vessels. Specifics on LA anatomy have been previously detailed[17,18]. The LA has four important mechanical functions across three phases (Figure 1): (1) a reservoir (phase) to receive blood and store kinetic energy (as pressure) for LV filling that coincides with mitral valve closure to opening and ventricular events of isovolumic contraction, ejection and isovolumic relaxation; (2) a conduit (phase) for transiting blood (in early diastole) from the pulmonary veins to the LV after a pressure gradient develops to open the mitral valve and also passively during diastasis and is dependent on LV relaxation and preload; (3) a pump (contractile phase) to provide a “booster” depending on the preload, afterload, intrinsic contractility and electromechanical coupling [term defines the time between atrial electrical activation and mechanical activation (19)] to augment LV filling in late diastole; and (4) a suction effect to refill itself in early systole.

The LA contributes upto 30% of LV filling (The three phases can contribute around 40%, 35% and 25% respectively). LA flow from the pulmonary veins is continuous while LV filling is intermittent. The LA also acts as a volume sensor and regulates fluid balance by, neurohormonal function with production and regulation of natriuretic peptides, by regulatory (barometer) function via mechanoreceptors, and by interaction with renin angiotension aldosterone system/pathway (RAAS)[19-25].

***LV and diastole***

LV diastole coincides with LA systolic phase. Of the four parameters used to define diastolic function, three, LV relaxation, distensibility (restoring force) and stiffness (compliance) are predominately determined by LV characteristics and morphology. The fourth, LV filling or preload has significant LA contribution and is a compensation to maintain stroke volume (SV). Through LA and LV preload, afterload, contractility and electromechanical coupling passive and active atrioventricular connectivity are established. There are several publications that describe and evaluate LV aspects of DHF are cited[1,3,12,13,19,26,27]. Diastole is described in four phases and these phases can be related to phasic LA events (Figure 2)[28]: (1) isovolumic relaxation during LA reservoir period; (2) rapid early filling; (3) diastasis during LA conduit phase; and (4) late filling, during atrial contraction phase.

***Left atrial remodelling***

When there is pressure and volume overload the process of atrial remodeling starts. In 220 healthy patients, age related LA indexed volumes changed only beyond the eight-decade[29]. In contrast, and without increasing LA size, changes in phasic atrial volumes and augmentation of LA contraction occur earlier, corresponding with age related alterations in LV diastolic relaxation[30,31]. Changes in the indexed LA volume (LAVi) appear to parallel the grade of diastolic diastolic dysfunction (DD)[22]. Atrial arrhythmias is an indepedent precipitant of atrial remodeling. The response of atrial cell to external stress incites hypertrophy, fibrosis and subsequently LA dilatation and hypocontractility[21]. LA dysfunction may alter the reservoir and conduit functions of the atrium and reduce the ability to absorb increases in LVEDP being transmitted to the pulmonary vasculature, for which there is a threshold similar to LV Frank-Starling mechanics[32]. Loss of phasic LA pump function can also lead to symptoms by reducing late LV diastolic filling, which is more marked when there is preexisting systolic impairment[25,33]. Pressure load to the LA can be seen in mitral stenosis and or increased LVEDP. Volume loading occurs in mitral regurgitation, intracardiac shunts or arteriovenous fistulae and high cardiac output states. These have to be factored in using LA metric when evaluating DD.

**ROLE OF ATRIUM IN DHF WORKUP**

In a patient with SOB, echocardiography will firstly confirm LV systolic function (*i.e.,* normal or mildly impaired ventricle (LVEF > 50%). A body of evidence is developing however to suggest that “sub clinical” systolic dysfunction such as reduced longitudinal LV shortening are present, and occur before the alteration seen in LVEF. At this stage the clinical context for DHF is evolving. Cardiac imaging with echocardiography however does not directly measure LVEDP and infers this by changes in volume, blood and tissue velocities. Invasive measures (LV pressure tracing or pressure volume data) and natriuretic peptides can provide direct information on myocardial stretch and hence diastolic abnormalities[15]. However, the noninvasively evaluated e/e’ (ratio of early diastolic transmitral velocity to early diastolic tissue velocity) serves as a surrogate of LV EDP.

Some patients manifest symptoms during exercise and this similarly can be assessed[27,34-37]. There is no single non-invasive index that confirms or rules out the diagnosis, however using a combination of parameters, this can be achieved (Figure 3). Furthermore it is unclear if any one parameter provides greater weight than another.

***Left atrium as a biomarker***

There is a volume of data to support LA enlargement and adverse cardiovascular outcomes independent of age, gender and the major comorbid cardiovascular risk factors[22,38,39]. In fact LA dilatation should be considered pathological before the eight decade[28]. Among 2042 residents in Olmstead County, Minnesota over 45 years of age, LAVi predicted all cause mortality, as did the grade of DD[40]. From the same community, retrospective analysis of 1160 participants (> 65 years) followed for 3.8 ± 2.7 years, LAVi >32 mL/m2 predicted risk for first cardiovascular event (*P* = 0.003)[41]. Several studies with 851 and 1495 patients over 65 years of age, found that measures of LA size predicted new development of HF[42,43]. This risk was also demonstrated in 483 younger participants (mean age 47 years) followed for 6.8 years, where Leung et al showed that LAVi > 24 mL/m2 was the only independent echocardiographic predictor of cardiovascular death, congestive heart failure, myocardial infarction, stroke and atrial fibrillation. Using a variety of methods, studies show an increase in cardiac and all cause mortality in a general population[44,45], following myocardial infarction[46,47], and with dilated cardiomyopathy[48]; predicts ischemic heart disease[41,49,50], atrial fibrillation and stroke[40,41,44,49-56].

Alteration in LA mechanics (function), with or without LA dilatation, correlate with disease states such as hypertension, diabetes and renal impairment, and to adverse outcomes[57,58]. In 1802 participants of the Dallas Heart study imaged with magnetic resonance imaging, decreasing LA emptying fraction was independently associated with mortality but not LAVi[59]. In HF the reservoir and conduit functions are inversely related with Doppler parameters of DD and LVEDP. As HF progresses atrial contractility also gradually declines[60-62]. Early changes in LA mechanics, correlations with comorbidities and disease severity and recovery with treatments, have been demonstrated for hypertension[63-65], atrial fibrillation[66-70] and valvular heart disease, using a variety of methods[19,22].

***Left atrium as a barometer***

LA changes particularly the LAVi reflects the chronicity and cumulative effects of changes in LV filling pressures. While the LAVi does not reflect acute changes in LV pressures it can be used as a barometer for chronically elevated LV filling pressures. This change can persist for some time after pressures have normalized. Increased LA volume can also be seen in athletes, bradycardia, anemia, high output states, atrial arrhythmias and mitral valve disease, independent of diastolic dysfunction. When these conditions are excluded LAVi > 34 mL/m2 should alert treating physicians to the possibility of DD and raised LV filling pressures[15].

To summarize the data, firstly LA size is a marker of health in a population; secondly a change in size highlights a remodeling process that predicts adverse outcomes; and thirdly alterations in LA size and mechanics potentially is caused by alterations in LV diastolic filling abnormalities due to atrioventricular interdependence[40].

**IMAGING THE LEFT ATRIUM**

Conventional echocardiography is sufficient to assess atrial size, but a combination of conventional and novel techniques are required to assess atrial mechanical functions.

***Left atrial size assessment***

M-mode and 2D echocardiography measuring the antero-posterior diameter, as performed in early studies, is now agreed to be an inadequate measure of LA size. Both the American and European Society of Echocardiography are in consensus that LAV using either the ellipsoid model or Simpson’s method in two and four chamber apical views is more accurate as LA enlargement occurs asymmetrically. When the LAV is indexed (LAVi) it provides the strongest association, most sensitive predictor and risk stratification tool for cardiovascular outcomes[2,3,22,38]. A detailed description of LAV is highlighted below[55].

**LA passive volumes consist of:** (1)preatrial contraction volume (VpreA), measured at the onset of the P-wave on an electrocardiogram (ECG); (2) minimal LA volume (Vmin), measured at the closure of the mitral valve in end-diastole; and (3) maximal LA volume (Vmax), measured just before the opening of the mitral valve in end-systole.

**LA active volumes are: (1)** LA reservoir volume (Vmax - Vmin); (2) LA conduit volume (LV total SV - LA reservoir volume); (3) LA passive emptying volume (Vmax - VpreA); and (4) LA contractile volume (VpreA - Vmin).

Physiological associations of LA size have been noted with body size and gender, but these differences are not apparent once indexed to BSA. Age related changes are seen at the extremes but not with normal aging. Based on the sensitivity and specificity for predicting cardiac events, population studies have shown mean LAVi by biplane Simpsons or area length method was between 20-23 ± 6-7 mL/m2, giving a normal value of 22 ± 6 mL/m2[31,40,44,51,53]. In the guidelines, 1 standard deviation (SD) from the mean >28 mL/m2 is considered LA enlargement and 2 SD from the mean > 34 mL/m2 for DD[3,18,21]. Pressure load to the LA can be seen in mitral stenosis and or increased LVEDP. Volume loading occurs in mitral regurgitation, intracardiac shunts or arteriovenous fistulae and high cardiac output states. These have to be factored in evaluating DD and LA changes. Factoring these conditions LAVi has been shown to strongly correlate with the degree of DD and even differentiate between normal and pseudonormal filling patterns[19,20,22,50,71,72].

***Left atrial function assessment***

The gold standard test atrial volume loop is invasive and not routinely available. Four established echocardiographic parameters can provide information on the varying phases of LA function with advantages and disadvantages (Table 1).

2D volumetric analysis (the volume method) is the simplest but requires skill in obtaining the images and is time consuming. It uses LA volume at their maximum, minimum and just before LA systole to determine function.

Spectral (pulsed wave) Doppler of transmitral flow and pulmonary veins (sampled at mitral leaflet tips) are readily available, easy to use but only provides estimate of LA function. It is dependent on immediate loading conditions and can be affected by myocardial tethering acquisition angle, heart rates, atrial fibrillation, conduction system disease, age related reductions in LV diastolic compliance, altered hemodynamics and mitral valve disease. Peak transmitral A wave velocity, velocity time integral and atrial fraction can be used to measure LA contractile function and has been beneficial in following correction of atrial fibrillation with cardioversion, cathether ablation or surgery[53,71-78]. The atrial ejection force can be calculated with several assumptions of the density of blood and a circular mitral annulus area, where diameter is measured in 4-chamber view. This has found correlation with return of atrial function post cardioversion, adverse cardiovascular remodeling and cardiovascular events[79,80], although significant technical limitations persist[20]. Importantly all Doppler measurements can only be performed in sinus rhythm.

Tissue Doppler imaging of intrinsic myocardial velocity (*e.g.,* mitral annulus), can provide regional and when averaged from several sites, global function. It is a low–velocity and high amplitude signal and has the advantage of being load independent. Tissue Doppler has deficiencies of angle dependency (acquisition angle - long axis), is dependent on cardiac motion and myocardial properties such as tethering and annular sampling site. A’ values has been shown to be a useful surrogate of global LA function, while all parameters (S’, E’ and A’) provide useful prognostic information[20,31,81-86].

Deformation analysis with strain and the speed of deformation with strain rate imaging can quantify regional and global function independent of tethering. Values however show regional variation[63,73]. Positive values are seen with chamber dilatation and wall stretch and negative values with contraction. Similarly this method has shown correlations with clinical outcomes and prognosis such as maintenance of sinus rhythm and atrial mechanics in atrial fibrillation[67-71,87], New York Heart Association Functional Class[97], LA contractile function[63,65], hypertensive heart disease[64,66] and valvular heart disease[19].

**EXERCISE DIASTOLOGY**

SOB and exercise intolerance due to HFpEF, should demonstrate an increased LVEDP with exercise. The proven exercise protocols are stress echocardiography, combined stress echocardiography and cardiopulmonary stress test, and right heart catheterization with exercise[27,34-36,88-98]. HFpEF is a systemic condition with an interaction of the primary cause coupled with secondary pathophysiological changes in the LV and LA. The continuity of the vasculature places the cardiac and peripheral endothelial beds at risk of injury when chronically exposed to risk factors. This loss of compliance or efficiency can see disproportionate rises in LV filing pressures, which can be buffered for, *e.g.,* by changes in atrial function[27]. Thus a combination of deficits in arterial-ventricular-atrial function will be present in symptomatic individuals where a rise in LVEDP or LA pressure is the common denominator.

Burgess *et al*[91] studied 37 patients at baseline and after supine cycle ergometry, and found that the e/e’ of >13 correlates with an elevated LVEDP during exercise. In another 166 patients post-exercise e/e’ >13 was highly specific (90%) for stratifying an exercise capacity of < 8METs or >8 METs[91]. Nedeljkovic *et al*[89] studied 87 patients with HTN, exertional SOB and normal resting LV function with combined exercise stress echocardiography cardiopulmonary testing to identify masked HFpEF found correlations between e/e’ >15 and reduced peak V02 and other parameters with high sensitivity and specificity. Maeder *et al*[36] identified 14 patients with diagnosed HFpEF and matched controls, who subsequently underwent supine cycle ergometer exercise, found that patients with HFpEF achieved a similar pulmonary capillary wedge pressure (PCWP) to asymptomatic controls at a much lower workload. However, contrary to Burgess *et al*[91], the e/e’ did not reflect the hemodynamic changes during exercise in HFNEF patients.

Pulmonary artery pressures, which can act as a surrogate for elevated left sided filling pressures can also be used. This spectral Doppler method measures the tricuspid regurgitation (TR) jet velocity and applies the formula 4V2 + right atrial pressure (V = Doppler velocity of regurgitant jet). Standardized measures of right atrial pressure are readily available from guideline and textbooks. While the non-invasive stress test is practical and translatable, translational gaps persists partly due discrepancies in role of e:e’ found in Burgess *et al*[91] and Maeder *et al*[36], identifying a suitable adjunct for pulmonary artery pressures when TR is absent, and establishing values that constitute elevated pressures across the spectrum of resting diastolic profiles, and baseline pulmonary artery pressures.

**RATIONALE AND ARGUMENTS FOR FUTURE CLINICAL STUDIES OF DHF**

***Clinical correlation of atrial derived parameters***

The current understanding of diastology does not allow us to definitively correlate symptoms to the varying changes in diastolic profiles. In addition no single parameter can be used to determine the diagnoses. In the process of grading diastolic abnormalities changes in the mitral valve velocity profiles and tissue Doppler occur as a normal part of aging. With the advent of exercise diastology and the inclusion of left atrial volume in the most recent guidelines, highlights the importance of looking for evidence that LV filling pressures are elevated in a patient with SOB. We thus feel that an important first step is to document an increase in intracardiac pressures and the subsequent steps should go on to explore the causes for this both in the LV and LA*.* The bases for the later is that many of the atrial derived parameters are used to define LV diastolic function, with little emphasis on how changes in LA function could alter this.

***Terminology***

DHF syndrome is a broad categorisation of a complex syndrome with multiple contributors where the end result is SOB and clinical impairment. Unlike SHF where the entirety of the syndrome is coupled with an impairment of LV myocardial contractility, in HFpEF it remains unclear how the interplay between degrees of LV stiffness and LA dynamics contributes to symptoms. Thus terminology in HFpEF should reflect the atrioventricular interaction in LV diastole. Lets explore several hypothetical case examples: (1) HfpEF – With predominantly impaired LV relaxation. In this scenario a patient would have clinical symptoms and signs, abnormal LV diastolic parameters, has demonstrated elevation of LVEDP (at rest or exercise), without significant LA abnormalities, and a shift of LVEDP and volume curve to the left; (2) HFpEF – secondary to atrial dysfunction/atrial fibrillation. In this scenario the patients have similar presentation as above, however despite rate control, remains symptomatic. Restoration of sinus rhythm correlates with clinical improvement of symptoms.

Part of establishing the terminology requires an improved understanding of all aspects of LV and LA abnormalities.

***Future clinical studies***

The premise of any future study should be based on consolidating the diagnosis with this point in mind: “In a patient with SOB and normal LVEF the diagnosis of HFpEF can only be consolidated by reproducibly demonstrating an elevation of LVEDP or LA pressure before treatment, that this elevation is outside a physiological norm and correlates with the patients symptoms”. The premise of therapeutic studies while not the aim of this paper should also focus on atrioventricular pathophysiological derangements. From this point we can explore the steps in cardiac investigations.

**Screening:** (1) firstly all patients should have a screening echocardiogram; and (2) epidemiology studies are still needed to correlate the chronology of diastolic parameters with time and symptoms.

**Demonstrating increased LVEDP:** Firstly, we need to demonstrate an increase in LVEDP, and secondly we need to demonstrate the abnormality in the atrioventricular context. An important question then is should exercise stress testing be a routine part of DHF work-up? Due to cost, availability and the sheer volume of patients’ invasive tests seem unrealistic, however non-invasive exercise echocardiography could screen patients needing an invasive test. Second, what parameters to use?(1) pulmonary artery pressure elevations detected by exercise stress echocardiography can be a surrogate for LVEDP. Excluding other causes for pulmonary hypertension is important. When TR is absent patients could go onto an invasive exercise right heart study; and (2) The role of e/e’ and other variations in spectral and tissue Doppler parameters requires further attention. There is conflicting data from studies in the former and a lack of data for the latter[36,99]. Thirdly, natriuretic peptides: Are secreted in response to atrial (atrial natriuretic peptides) or ventricular (brain natriuretic peptides) stretch. These factors have different biological properties such as chamber secreted and half-life can be exploited for diagnosis and monitoring. In clinical translation its utility with exercise stress echocardiography as a surrogate for an invasive right heart study derived LVEDP is yet to be defined[95].

**Atrial function:** Is difficult to assess both at baseline and with exercise, as there are no clinically friendly tools. As many of the echocardiographic derived DHF parameters correlate with atrial mechanics, understanding how these parameters change with LA disease will better inform LV diastology. Several examples: From an invasive study in dogs undergoing exercise, it is observed that reservoir and booster functions increase but not conduit function[96]; in 50 HFpEF patients, using late diastolic mitral annular velocity and calculated left atrial reserve index, found reduced LA function with exercise that could contribute to symptoms in addition to LV systolic and diastolic abnormalities[97]. An improved understanding could also help inform future therapies targeting the LA.

**Reliability in monitoring:** Issues that need to be addressed are inter and intraobserver variability and the correlation of diastolic parameters following treatment and with changes in clinical status over time[100].

**Diastolic compensation and chronology:** For patients who have abnormal baseline diastology who do not demonstrate increases in LVEDP with exercise, we will need to find satisfactory means to exclude HFpEF from the diagnosis. This will require improved understanding of diastolic compensation in the chronology of myocardial cellular function, where a different result could be elicited with different conditions.

**CONCLUSION**

SOB is a common symptom presentation to cardiology clinics. Clinical workup can point toward coronary artery disease, HFrEF, respiratory causes or anemia. There is also a sizable group where differentiation is required between deconditioning, obesity or HFpEF. Thus diagnosis of HFpEF has and still remains difficult where no one parameter we have is “a smoking gun”. Baseline echocardiographic parameters have translated into flow diagrams published in the latest guidelines. There remain however important gaps in the understanding of this syndrome: (1) diastolic function is complex in that it requires functional mechanics of both the atrium and ventricle, where less importance has been placed in understanding LA function; (2) exercise stress echocardiography is underutilized in the diagnostic work-up; (3) our understanding of the baseline and subsequent parameters in its reproducibility and clinical translation requires more study; (4) the terminology defining the major contributor to HFpEF into atrial or ventricular dysfunction, should be explored; and (5) the translation of diagnostic findings into the clinical context such as relieving LVEDP, addressing myocardial stiffness with antifibrotics, correcting or augmenting atrial function and perhaps even devices to improve atrioventricular electrical or mechanical functions. To satisfactorily deliver optimal treatments more studies are needed to consolidate on our understanding and to confidently provide the diagnosis of HFpEF in a patient presenting with SOB.

**REFERENCES**

1. **Ponikowski P**, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GM, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P; Authors/Task Force Members; Document Reviewers. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. *Eur J Heart Fail* 2016; **18**: 891-975 [PMID: 27207191 DOI: 10.1002/ejhf.592]
2. **Paulus WJ**, Tschöpe C, Sanderson JE, Rusconi C, Flachskampf FA, Rademakers FE, Marino P, Smiseth OA, De Keulenaer G, Leite-Moreira AF, Borbély A, Edes I, Handoko ML, Heymans S, Pezzali N, Pieske B, Dickstein K, Fraser AG, Brutsaert DL. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. *Eur Heart J* 2007; **28**: 2539-2550 [PMID: 17428822 DOI: 10.1093/eurheartj/ehm037]
3. **Nagueh SF**, Smiseth OA, Appleton CP, Byrd BF 3rd, Dokainish H, Edvardsen T, Flachskampf FA, Gillebert TC, Klein AL, Lancellotti P, Marino P, Oh JK, Alexandru Popescu B, Waggoner AD; Houston, Texas; Oslo, Norway; Phoenix, Arizona; Nashville, Tennessee; Hamilton, Ontario, Canada; Uppsala, Sweden; Ghent and Liège, Belgium; Cleveland, Ohio; Novara, Italy; Rochester, Minnesota; Bucharest, Romania; and St. Louis, Missouri. Recommendations for the Evaluation of Left Ventricular Diastolic Function by Echocardiography: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. *Eur Heart J Cardiovasc Imaging* 2016; **17**: 1321-1360 [PMID: 27422899 DOI: 10.1016/j.echo.2016.01.011]
4. **Kovács SJ**. Diastolic function in heart failure. *Clin Med Insights Cardiol* 2015; **9**: 49-55 [PMID: 25922587 DOI: 10.4137/CMC.S18743]
5. **Lee DS**, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, Tu JV, Levy D. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. *Circulation* 2009; **119**: 3070-3077 [PMID: 19506115 DOI: 10.1161/CIRCULATIONAHA.108.815944]
6. **Owan TE**, Redfield MM. Epidemiology of diastolic heart failure. *Prog Cardiovasc Dis* 2005; **47**: 320-332 [PMID: 16003647 DOI: 10.1016/j.pcad.2005.02.010]
7. **Owan TE**, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. *N Engl J Med* 2006; **355**: 251-259 [PMID: 16855265 DOI: 10.1056/NEJMoa052256]
8. **Lam CS**, Donal E, Kraigher-Krainer E, Vasan RS. Epidemiology and clinical course of heart failure with preserved ejection fraction. *Eur J Heart Fail* 2011; **13**: 18-28 [PMID: 20685685 DOI: 10.1093/eurjhf/hfq121]
9. **Gerber Y**, Weston SA, Redfield MM, Chamberlain AM, Manemann SM, Jiang R, Killian JM, Roger VL. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. *JAMA Intern Med* 2015; **175**: 996-1004 [PMID: 25895156 DOI: 10.1001/jamainternmed.2015.0924]
10. **Meta-analysis Global Group in Chronic Heart Failure (MAGGIC)**. The survival of patients with heart failure with preserved or reduced left ventricular ejection fraction: an individual patient data meta-analysis. *Eur Heart J* 2012; **33**: 1750-1757 [PMID: 21821849 DOI: 10.1093/eurheartj/ehr254]
11. **Gottdiener JS**, McClelland RL, Marshall R, Shemanski L, Furberg CD, Kitzman DW, Cushman M, Polak J, Gardin JM, Gersh BJ, Aurigemma GP, Manolio TA. Outcome of congestive heart failure in elderly persons: influence of left ventricular systolic function. The Cardiovascular Health Study. *Ann Intern Med* 2002; **137**: 631-639 [PMID: 12379062 DOI: 10.7326/0003-4819-137-8-200210150-00006]
12. **Borlaug BA**. The pathophysiology of heart failure with preserved ejection fraction. *Nat Rev Cardiol* 2014; **11**: 507-515 [PMID: 24958077 DOI: 10.1038/nrcardio.2014.83]
13. **Kovács Á**, Papp Z, Nagy L. Causes and pathophysiology of heart failure with preserved ejection fraction. *Heart Fail Clin* 2014; **10**: 389-398 [PMID: 24975903 DOI: 10.1016/j.hfc.2014.04.002]
14. **Phan TT**, Shivu GN, Abozguia K, Sanderson JE, Frenneaux M. The pathophysiology of heart failure with preserved ejection fraction: from molecular mechanisms to exercise haemodynamics. *Int J Cardiol* 2012; **158**: 337-343 [PMID: 21794933 DOI: 10.1016/j.ijcard.2011.06.113]
15. **Flachskampf FA**, Biering-Sørensen T, Solomon SD, Duvernoy O, Bjerner T, Smiseth OA. Cardiac Imaging to Evaluate Left Ventricular Diastolic Function. *JACC Cardiovasc Imaging* 2015; **8**: 1071-1093 [PMID: 26381769 DOI: 10.1016/j.jcmg.2015.07.004]
16. **Nanayakkara S**, Kaye DM. Management of heart failure with preserved ejection fraction: a review. *Clin Ther* 2015; **37**: 2186-2198 [PMID: 26385583 DOI: 10.1016/j.clinthera.2015.08.005]
17. **Corradi D**, Maestri R, Macchi E, Callegari S. The atria: from morphology to function. *J Cardiovasc Electrophysiol* 2011; **22**: 223-235 [PMID: 20812935 DOI: 10.1111/j.1540-8167.2010.01887.x]
18. **Ho SY**, Sanchez-Quintana D, Cabrera JA, Anderson RH. Anatomy of the left atrium: implications for radiofrequency ablation of atrial fibrillation. *J Cardiovasc Electrophysiol* 1999; **10**: 1525-1533 [PMID: 10571372]
19. **Todaro MC**, Choudhuri I, Belohlavek M, Jahangir A, Carerj S, Oreto L, Khandheria BK. New echocardiographic techniques for evaluation of left atrial mechanics. *Eur Heart J Cardiovasc Imaging* 2012; **13**: 973-984 [PMID: 22909795 DOI: 10.1093/ehjci/jes174]
20. **Leung DY**, Boyd A, Ng AA, Chi C, Thomas L. Echocardiographic evaluation of left atrial size and function: current understanding, pathophysiologic correlates, and prognostic implications. *Am Heart J* 2008; **156**: 1056-1064 [PMID: 19032999 DOI: 10.1016/j.ahj.2008.07.021]
21. **Rossi A**, Gheorghiade M, Triposkiadis F, Solomon SD, Pieske B, Butler J. Left atrium in heart failure with preserved ejection fraction: structure, function, and significance. *Circ Heart Fail* 2014; **7**: 1042-1049 [PMID: 25415957 DOI: 10.1161/CIRCHEARTFAILURE.114.001276]
22. **Hoit BD**. Left atrial size and function: role in prognosis. *J Am Coll Cardiol* 2014; **63**: 493-505 [PMID: 24291276 DOI: 10.1016/j.jacc.2013.10.055]
23. **Blume GG**, Mcleod CJ, Barnes ME, Seward JB, Pellikka PA, Bastiansen PM, Tsang TS. Left atrial function: physiology, assessment, and clinical implications. *Eur J Echocardiogr* 2011; **12**: 421-430 [PMID: 21565866 DOI: 10.1093/ejechocard/jeq175]
24. **Patel DA**, Lavie CJ, Milani RV, Shah S, Gilliland Y. Clinical implications of left atrial enlargement: a review. *Ochsner J* 2009; **9**: 191-196 [PMID: 21603443]
25. **Abhayaratna WP**, Seward JB, Appleton CP, Douglas PS, Oh JK, Tajik AJ, Tsang TS. Left atrial size: physiologic determinants and clinical applications. *J Am Coll Cardiol* 2006; **47**: 2357-2363 [PMID: 16781359 DOI: 10.1016/j.jacc.2006.02.048]
26. **Asrar Ul Haq M**, Mutha V, Rudd N, Hare DL, Wong C. Heart failure with preserved ejection fraction - unwinding the diagnosis mystique. *Am J Cardiovasc Dis* 2014; **4**: 100-113 [PMID: 25360388]
27. **Asrar Ul Haq M**, Goh CY, Levinger I, Wong C, Hare DL. Clinical utility of exercise training in heart failure with reduced and preserved ejection fraction. *Clin Med Insights Cardiol* 2015; **9**: 1-9 [PMID: 25698883 DOI: 10.4137/CMC.S21372]
28. **Mitchell JR**, Wang JJ. Expanding application of the Wiggers diagram to teach cardiovascular physiology. *Adv Physiol Educ* 2014; **38**: 170-175 [PMID: 24913453 DOI: 10.1152/advan.00123.2013]
29. **Boyd AC**, Schiller NB, Leung D, Ross DL, Thomas L. Atrial dilation and altered function are mediated by age and diastolic function but not before the eighth decade. *JACC Cardiovasc Imaging* 2011; **4**: 234-242 [PMID: 21414570 DOI: 10.1016/j.jcmg.2010.11.018]
30. **Spencer KT**, Mor-Avi V, Gorcsan J 3rd, DeMaria AN, Kimball TR, Monaghan MJ, Perez JE, Weinert L, Bednarz J, Edelman K, Kwan OL, Glascock B, Hancock J, Baumann C, Lang RM. Effects of aging on left atrial reservoir, conduit, and booster pump function: a multi-institution acoustic quantification study. *Heart* 2001; **85**: 272-277 [PMID: 11179264]
31. **Thomas L**, Levett K, Boyd A, Leung DY, Schiller NB, Ross DL. Compensatory changes in atrial volumes with normal aging: is atrial enlargement inevitable? *J Am Coll Cardiol* 2002; **40**: 1630-1635 [PMID: 12427416]
32. **Blondheim DS**, Osipov A, Meisel SR, Frimerman A, Shochat M, Shotan A. Relation of left atrial size to function as determined by transesophageal echocardiography. *Am J Cardiol* 2005; **96**: 457-463 [PMID: 16054483 DOI: 10.1016/j.amjcard.2005.03.101]
33. **Appleton CP**, Hatle LK, Popp RL. Relation of transmitral flow velocity patterns to left ventricular diastolic function: new insights from a combined hemodynamic and Doppler echocardiographic study. *J Am Coll Cardiol* 1988; **12**: 426-440 [PMID: 3392336 DOI: 10.1016/0735-1097(88)90416-0]
34. **Kitzman DW**, Higginbotham MB, Cobb FR, Sheikh KH, Sullivan MJ. Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. *J Am Coll Cardiol* 1991; **17**: 1065-1072 [PMID: 2007704 DOI: 10.1016/0735-1097(91)90832-T]
35. **Ha JW**, Oh JK, Pellikka PA, Ommen SR, Stussy VL, Bailey KR, Seward JB, Tajik AJ. Diastolic stress echocardiography: a novel noninvasive diagnostic test for diastolic dysfunction using supine bicycle exercise Doppler echocardiography. *J Am Soc Echocardiogr* 2005; **18**: 63-68 [PMID: 15637491 DOI: 10.1016/j.echo.2004.08.033]
36. **Maeder MT**, Thompson BR, Brunner-La Rocca HP, Kaye DM. Hemodynamic basis of exercise limitation in patients with heart failure and normal ejection fraction. *J Am Coll Cardiol* 2010; **56**: 855-863 [PMID: 20813283 DOI: 10.1016/j.jacc.2010.04.040]
37. **Huis In 't Veld AE**, de Man FS, van Rossum AC, Handoko ML. How to diagnose heart failure with preserved ejection fraction: the value of invasive stress testing. *Neth Heart J* 2016; **24**: 244-251 [PMID: 26914917 DOI: 10.1007/s12471-016-0811-0]
38. **Tsang TS**, Abhayaratna WP, Barnes ME, Miyasaka Y, Gersh BJ, Bailey KR, Cha SS, Seward JB. Prediction of cardiovascular outcomes with left atrial size: is volume superior to area or diameter? *J Am Coll Cardiol* 2006; **47**: 1018-1023 [PMID: 16516087 DOI: 10.1016/j.jacc.2005.08.077]
39. **Katayama T**, Fujiwara N, Tsuruya Y. Factors contributing to left atrial enlargement in adults with normal left ventricular systolic function. *J Cardiol* 2010; **55**: 196-204 [PMID: 20206072 DOI: 10.1016/j.jjcc.2009.10.008]
40. **Pritchett AM**, Mahoney DW, Jacobsen SJ, Rodeheffer RJ, Karon BL, Redfield MM. Diastolic dysfunction and left atrial volume: a population-based study. *J Am Coll Cardiol* 2005; **45**: 87-92 [PMID: 15629380 DOI: 10.1016/j.jacc.2004.09.054]
41. **Tsang TS**, Barnes ME, Gersh BJ, Takemoto Y, Rosales AG, Bailey KR, Seward JB. Prediction of risk for first age-related cardiovascular events in an elderly population: the incremental value of echocardiography. *J Am Coll Cardiol* 2003; **42**: 1199-1205 [PMID: 14522480 DOI: 10.1016/S0735-1097(03)00943-4]
42. **Gottdiener JS**, Kitzman DW, Aurigemma GP, Arnold AM, Manolio TA. Left atrial volume, geometry, and function in systolic and diastolic heart failure of persons > or =65 years of age (the cardiovascular health study). *Am J Cardiol* 2006; **97**: 83-89 [PMID: 16377289 DOI: 10.1016/j.amjcard.2005.07.126]
43. **Takemoto Y**, Barnes ME, Seward JB, Lester SJ, Appleton CA, Gersh BJ, Bailey KR, Tsang TS. Usefulness of left atrial volume in predicting first congestive heart failure in patients &gt; or = 65 years of age with well-preserved left ventricular systolic function. *Am J Cardiol* 2005; **96**: 832-836 [PMID: 16169372 DOI: 10.1016/j.amjcard.2005.05.031]
44. **Gardin JM**, McClelland R, Kitzman D, Lima JA, Bommer W, Klopfenstein HS, Wong ND, Smith VE, Gottdiener J. M-mode echocardiographic predictors of six- to seven-year incidence of coronary heart disease, stroke, congestive heart failure, and mortality in an elderly cohort (the Cardiovascular Health Study). *Am J Cardiol* 2001; **87**: 1051-1057 [PMID: 11348601 DOI: 10.1016/S0002-9149(01)01460-6]
45. **Laukkanen JA**, Kurl S, Eränen J, Huttunen M, Salonen JT. Left atrium size and the risk of cardiovascular death in middle-aged men. *Arch Intern Med* 2005; **165**: 1788-1793 [PMID: 16087829 DOI: 10.1001/archinte.165.15.1788]
46. **Moller JE**, Hillis GS, Oh JK, Seward JB, Reeder GS, Wright RS, Park SW, Bailey KR, Pellikka PA. Left atrial volume: a powerful predictor of survival after acute myocardial infarction. *Circulation* 2003; **107**: 2207-2212 [PMID: 12695291 DOI: 10.1161/01.CIR.0000066318.21784.43]
47. **Beinart R**, Boyko V, Schwammenthal E, Kuperstein R, Sagie A, Hod H, Matetzky S, Behar S, Eldar M, Feinberg MS. Long-term prognostic significance of left atrial volume in acute myocardial infarction. *J Am Coll Cardiol* 2004; **44**: 327-334 [PMID: 15261927 DOI: 10.1016/j.jacc.2004.03.062]
48. **Rossi A**, Cicoira M, Zanolla L, Sandrini R, Golia G, Zardini P, Enriquez-Sarano M. Determinants and prognostic value of left atrial volume in patients with dilated cardiomyopathy. *J Am Coll Cardiol* 2002; **40**: 1425 [PMID: 12392832 DOI: 10.1016/S0735-1097(02)02305-7]
49. **Pritchett AM**, Jacobsen SJ, Mahoney DW, Rodeheffer RJ, Bailey KR, Redfield MM. Left atrial volume as an index of left atrial size: a population-based study. *J Am Coll Cardiol* 2003; **41**: 1036-1043 [PMID: 12651054 DOI: 10.1016/S0735-1097(02)02981-9]
50. **Osranek M**, Bursi F, Bailey KR, Grossardt BR, Brown RD Jr, Kopecky SL, Tsang TS, Seward JB. Left atrial volume predicts cardiovascular events in patients originally diagnosed with lone atrial fibrillation: three-decade follow-up. *Eur Heart J* 2005; **26**: 2556-2561 [PMID: 16141257 DOI: 10.1093/eurheartj/ehi483]
51. **Barnes ME**, Miyasaka Y, Seward JB, Gersh BJ, Rosales AG, Bailey KR, Petty GW, Wiebers DO, Tsang TS. Left atrial volume in the prediction of first ischemic stroke in an elderly cohort without atrial fibrillation. *Mayo Clin Proc* 2004; **79**: 1008-1014 [PMID: 15301328 DOI: 10.4065/79.8.1008]
52. **Tsang TS**, Barnes ME, Bailey KR, Leibson CL, Montgomery SC, Takemoto Y, Diamond PM, Marra MA, Gersh BJ, Wiebers DO, Petty GW, Seward JB. Left atrial volume: important risk marker of incident atrial fibrillation in 1655 older men and women. *Mayo Clin Proc* 2001; **76**: 467-475 [PMID: 11357793 DOI: 10.4065/76.5.467]
53. **Di Tullio MR**, Sacco RL, Sciacca RR, Homma S. Left atrial size and the risk of ischemic stroke in an ethnically mixed population. *Stroke* 1999; **30**: 2019-2024 [PMID: 10512901 DOI: 10.1161/01.STR.30.10.2019]
54. **Benjamin EJ**, D'Agostino RB, Belanger AJ, Wolf PA, Levy D. Left atrial size and the risk of stroke and death. The Framingham Heart Study. *Circulation* 1995; **92**: 835-841 [PMID: 7641364 DOI: 10.1161/01.CIR.92.4.835]
55. **Vaziri SM**, Larson MG, Benjamin EJ, Levy D. Echocardiographic predictors of nonrheumatic atrial fibrillation. The Framingham Heart Study. *Circulation* 1994; **89**: 724-730 [PMID: 8313561 DOI: 10.1161/01.CIR.89.2.724]
56. **Caplan LR**, D'Cruz I, Hier DB, Reddy H, Shah S. Atrial size, atrial fibrillation, and stroke. *Ann Neurol* 1986; **19**: 158-161 [PMID: 3963758 DOI: 10.1002/ana.410190208]
57. **Leischik R**, Littwitz H, Dworrak B, Garg P, Zhu M, Sahn DJ, Horlitz M. Echocardiographic Evaluation of Left Atrial Mechanics: Function, History, Novel Techniques, Advantages, and Pitfalls. *Biomed Res Int* 2015; **2015**: 765921 [PMID: 26236735 DOI: 10.1155/2015/765921]
58. **Gupta S**, Matulevicius SA, Ayers CR, Berry JD, Patel PC, Markham DW, Levine BD, Chin KM, de Lemos JA, Peshock RM, Drazner MH. Left atrial structure and function and clinical outcomes in the general population. *Eur Heart J* 2013; **34**: 278-285 [PMID: 22782941 DOI: 10.1093/eurheartj/ehs188]
59. **Morris DA**, Gailani M, Vaz Pérez A, Blaschke F, Dietz R, Haverkamp W, Ozcelik C. Left atrial systolic and diastolic dysfunction in heart failure with normal left ventricular ejection fraction. *J Am Soc Echocardiogr* 2011; **24**: 651-662 [PMID: 21458230 DOI: 10.1016/j.echo.2011.02.004]
60. **Wakami K**, Ohte N, Asada K, Fukuta H, Goto T, Mukai S, Narita H, Kimura G. Correlation between left ventricular end-diastolic pressure and peak left atrial wall strain during left ventricular systole. *J Am Soc Echocardiogr* 2009; **22**: 847-851 [PMID: 19560662 DOI: 10.1016/j.echo.2009.04.026]
61. **Sirbu C**, Herbots L, D'hooge J, Claus P, Marciniak A, Langeland T, Bijnens B, Rademakers FE, Sutherland GR. Feasibility of strain and strain rate imaging for the assessment of regional left atrial deformation: a study in normal subjects. *Eur J Echocardiogr* 2006; **7**: 199-208 [PMID: 16054869 DOI: 10.1016/j.euje.2005.06.001]
62. **Mondillo S**, Cameli M, Caputo ML, Lisi M, Palmerini E, Padeletti M, Ballo P. Early detection of left atrial strain abnormalities by speckle-tracking in hypertensive and diabetic patients with normal left atrial size. *J Am Soc Echocardiogr* 2011; **24**: 898-908 [PMID: 21665431 DOI: 10.1016/j.echo.2011.04.014]
63. **Cameli M**, Caputo M, Mondillo S, Ballo P, Palmerini E, Lisi M, Marino E, Galderisi M. Feasibility and reference values of left atrial longitudinal strain imaging by two-dimensional speckle tracking. *Cardiovasc Ultrasound* 2009; **7**: 6 [PMID: 19200402 DOI: 10.1186/1476-7120-7-6]
64. **Kokubu N**, Yuda S, Tsuchihashi K, Hashimoto A, Nakata T, Miura T, Ura N, Nagao K, Tsuzuki M, Wakabayashi C, Shimamoto K. Noninvasive assessment of left atrial function by strain rate imaging in patients with hypertension: a possible beneficial effect of renin-angiotensin system inhibition on left atrial function. *Hypertens Res* 2007; **30**: 13-21 [PMID: 17460367 DOI: 10.1291/hypres.30.13]
65. **Saha SK**, Anderson PL, Caracciolo G, Kiotsekoglou A, Wilansky S, Govind S, Mori N, Sengupta PP. Global left atrial strain correlates with CHADS2 risk score in patients with atrial fibrillation. *J Am Soc Echocardiogr* 2011; **24**: 506-512 [PMID: 21477990 DOI: 10.1016/j.echo.2011.02.012]
66. **Kuppahally SS**, Akoum N, Burgon NS, Badger TJ, Kholmovski EG, Vijayakumar S, Rao SN, Blauer J, Fish EN, Dibella EV, Macleod RS, McGann C, Litwin SE, Marrouche NF. Left atrial strain and strain rate in patients with paroxysmal and persistent atrial fibrillation: relationship to left atrial structural remodeling detected by delayed-enhancement MRI. *Circ Cardiovasc Imaging* 2010; **3**: 231-239 [PMID: 20133512 DOI: 10.1161/CIRCIMAGING.109.865683]
67. **Kaya EB**, Tokgözoglu L, Aytemir K, Kocabas U, Tülümen E, Deveci OS, Köse S, Kabakçi G, Nazli N, Ozkutlu H, Oto A. Atrial myocardial deformation properties are temporarily reduced after cardioversion for atrial fibrillation and correlate well with left atrial appendage function. *Eur J Echocardiogr* 2008; **9**: 472-477 [PMID: 17826354 DOI: 10.1016/j.euje.2007.07.003]
68. **Schneider C**, Malisius R, Krause K, Lampe F, Bahlmann E, Boczor S, Antz M, Ernst S, Kuck KH. Strain rate imaging for functional quantification of the left atrium: atrial deformation predicts the maintenance of sinus rhythm after catheter ablation of atrial fibrillation. *Eur Heart J* 2008; **29**: 1397-1409 [PMID: 18436560 DOI: 10.1093/eurheartj/ehn168]
69. **Thomas L**, McKay T, Byth K, Marwick TH. Abnormalities of left atrial function after cardioversion: an atrial strain rate study. *Heart* 2007; **93**: 89-95 [PMID: 16818487 DOI: 10.1136/hrt.2006.088609]
70. **Abhayaratna WP**, Fatema K, Barnes ME, Seward JB, Gersh BJ, Bailey KR, Casaclang-Verzosa G, Tsang TS. Left atrial reservoir function as a potent marker for first atrial fibrillation or flutter in persons &gt; or = 65 years of age. *Am J Cardiol* 2008; **101**: 1626-1629 [PMID: 18489941 DOI: 10.1016/j.amjcard.2008.01.051]
71. **Barberato SH**, Pecoits-Filho R. Usefulness of left atrial volume for the differentiation of normal from pseudonormal diastolic function pattern in patients on hemodialysis. *J Am Soc Echocardiogr* 2007; **20**: 359-365 [PMID: 17400114 DOI: 10.1016/j.echo.2006.09.002]
72. **Tsang TS**, Barnes ME, Gersh BJ, Bailey KR, Seward JB. Left atrial volume as a morphophysiologic expression of left ventricular diastolic dysfunction and relation to cardiovascular risk burden. *Am J Cardiol* 2002; **90**: 1284-1289 [PMID: 12480035 DOI: 10.1016/S0002-9149(02)02864-3]
73. **Cianciulli TF**, Saccheri MC, Lax JA, Bermann AM, Ferreiro DE. Two-dimensional speckle tracking echocardiography for the assessment of atrial function. *World J Cardiol* 2010; **2**: 163-170 [PMID: 21160748 DOI: 10.4330/wjc.v2.i7.163]
74. **Manning WJ**, Silverman DI, Katz SE, Riley MF, Doherty RM, Munson JT, Douglas PS. Temporal dependence of the return of atrial mechanical function on the mode of cardioversion of atrial fibrillation to sinus rhythm. *Am J Cardiol* 1995; **75**: 624-626 [PMID: 7887393 DOI: 10.1016/S0002-9149(99)80632-8]
75. **Manning WJ**, Silverman DI, Katz SE, Riley MF, Come PC, Doherty RM, Munson JT, Douglas PS. Impaired left atrial mechanical function after cardioversion: relation to the duration of atrial fibrillation. *J Am Coll Cardiol* 1994; **23**: 1535-1540 [PMID: 8195510 DOI: 10.1016/0735-1097(94)90652-1]
76. **Thomas L**, Thomas SP, Hoy M, Boyd A, Schiller NB, Ross DL. Comparison of left atrial volume and function after linear ablation and after cardioversion for chronic atrial fibrillation. *Am J Cardiol* 2004; **93**: 165-170 [PMID: 14715341 DOI: 10.1016/j.amjcard.2003.09.033]
77. **Choong CY**, Herrmann HC, Weyman AE, Fifer MA. Preload dependence of Doppler-derived indexes of left ventricular diastolic function in humans. *J Am Coll Cardiol* 1987; **10**: 800-808 [PMID: 2958532 DOI: 10.1016/S0735-1097(87)80273-5]
78. **Klein AL**, Burstow DJ, Tajik AJ, Zachariah PK, Bailey KR, Seward JB. Effects of age on left ventricular dimensions and filling dynamics in 117 normal persons. *Mayo Clin Proc* 1994; **69**: 212-224 [PMID: 8133658 DOI: 10.1016/S0025-6196(12)61059-3]
79. **Manning WJ**, Silverman DI, Katz SE, Douglas PS. Atrial ejection force: a noninvasive assessment of atrial systolic function. *J Am Coll Cardiol* 1993; **22**: 221-225 [PMID: 8509545 DOI: 10.1016/0735-1097(93)90838-R]
80. **Chinali M**, de Simone G, Roman MJ, Bella JN, Liu JE, Lee ET, Best LG, Howard BV, Devereux RB. Left atrial systolic force and cardiovascular outcome. The Strong Heart Study. *Am J Hypertens* 2005; **18**: 1570-6; discussion 1577 [PMID: 16364827 DOI: 10.1016/j.amjhyper.2005.05.036]
81. **Yu CM**, Sanderson JE, Marwick TH, Oh JK. Tissue Doppler imaging a new prognosticator for cardiovascular diseases. *J Am Coll Cardiol* 2007; **49**: 1903-1914 [PMID: 17498573 DOI: 10.1016/j.jacc.2007.01.078]
82. **Hesse B**, Schuele SU, Thamilasaran M, Thomas J, Rodriguez L. A rapid method to quantify left atrial contractile function: Doppler tissue imaging of the mitral annulus during atrial systole. *Eur J Echocardiogr* 2004; **5**: 86-92 [PMID: 15113019 DOI: 10.1016/S1525-2167(03)00046-5]
83. **Wang M**, Yip GW, Wang AY, Zhang Y, Ho PY, Tse MK, Lam PK, Sanderson JE. Peak early diastolic mitral annulus velocity by tissue Doppler imaging adds independent and incremental prognostic value. *J Am Coll Cardiol* 2003; **41**: 820-826 [PMID: 12628728 DOI: 10.1016/S0735-1097(02)02921-2]
84. **Thomas L**, Levett K, Boyd A, Leung DY, Schiller NB, Ross DL. Changes in regional left atrial function with aging: evaluation by Doppler tissue imaging. *Eur J Echocardiogr* 2003; **4**: 92-100 [PMID: 12749870 DOI: 10.1053/euje.4.2.92]
85. **Lindström L**, Wranne B. Pulsed tissue Doppler evaluation of mitral annulus motion: a new window to assessment of diastolic function. *Clin Physiol* 1999; **19**: 1-10 [PMID: 10068862 DOI: 10.1046/j.1365-2281.1999.00137.x]
86. **Sohn DW**, Chai IH, Lee DJ, Kim HC, Kim HS, Oh BH, Lee MM, Park YB, Choi YS, Seo JD, Lee YW. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. *J Am Coll Cardiol* 1997; **30**: 474-480 [PMID: 9247521 DOI: 10.1016/S0735-1097(97)88335-0]
87. **Di Salvo G**, Caso P, Lo Piccolo R, Fusco A, Martiniello AR, Russo MG, D'Onofrio A, Severino S, Calabró P, Pacileo G, Mininni N, Calabró R. Atrial myocardial deformation properties predict maintenance of sinus rhythm after external cardioversion of recent-onset lone atrial fibrillation: a color Doppler myocardial imaging and transthoracic and transesophageal echocardiographic study. *Circulation* 2005; **112**: 387-395 [PMID: 16006491 DOI: 10.1161/CIRCULATIONAHA.104.463125]
88. **Penicka M**, Bartunek J, Trakalova H, Hrabakova H, Maruskova M, Karasek J, Kocka V. Heart failure with preserved ejection fraction in outpatients with unexplained dyspnea: a pressure-volume loop analysis. *J Am Coll Cardiol* 2010; **55**: 1701-1710 [PMID: 20394874 DOI: 10.1016/j.jacc.2009.11.076]
89. **Nedeljkovic I**, Banovic M, Stepanovic J, Giga V, Djordjevic-Dikic A, Trifunovic D, Nedeljkovic M, Petrovic M, Dobric M, Dikic N, Zlatar M, Beleslin B. The combined exercise stress echocardiography and cardiopulmonary exercise test for identification of masked heart failure with preserved ejection fraction in patients with hypertension. *Eur J Prev Cardiol* 2016; **23**: 71-77 [PMID: 26358991 DOI: 10.1177/2047487315604836]
90. **Oh JK**, Park SJ, Nagueh SF. Established and novel clinical applications of diastolic function assessment by echocardiography. *Circ Cardiovasc Imaging* 2011; **4**: 444-455 [PMID: 21772012 DOI: 10.1161/CIRCIMAGING.110.961623]
91. **Burgess MI**, Jenkins C, Sharman JE, Marwick TH. Diastolic stress echocardiography: hemodynamic validation and clinical significance of estimation of ventricular filling pressure with exercise. *J Am Coll Cardiol* 2006; **47**: 1891-1900 [PMID: 16682317 DOI: 10.1016/j.jacc.2006.02.042]
92. **Mezzani A**, Agostoni P, Cohen-Solal A, Corrà U, Jegier A, Kouidi E, Mazic S, Meurin P, Piepoli M, Simon A, Laethem CV, Vanhees L. Standards for the use of cardiopulmonary exercise testing for the functional evaluation of cardiac patients: a report from the Exercise Physiology Section of the European Association for Cardiovascular Prevention and Rehabilitation. *Eur J Cardiovasc Prev Rehabil* 2009; **16**: 249-267 [PMID: 19440156 DOI: 10.1097/HJR.0b013e32832914c8]
93. **Guazzi M**, Myers J, Peberdy MA, Bensimhon D, Chase P, Arena R. Cardiopulmonary exercise testing variables reflect the degree of diastolic dysfunction in patients with heart failure-normal ejection fraction. *J Cardiopulm Rehabil Prev* 2010; **30**: 165-172 [PMID: 20216325 DOI: 10.1097/HCR.0b013e3181d0c1ad]
94. **Guazzi M**, Myers J, Arena R. Cardiopulmonary exercise testing in the clinical and prognostic assessment of diastolic heart failure. *J Am Coll Cardiol* 2005; **46**: 1883-1890 [PMID: 16286176 DOI: 10.1016/j.jacc.2005.07.051]
95. **Hamasaki H.** The Effects of Exercise on Natriuretic Peptides in Individuals without Heart Failure. *Sports* 2016; **4:** 32 [DOI: 10.3390/sports4020032]
96. **Nishikawa Y**, Roberts JP, Tan P, Klopfenstein CE, Klopfenstein HS. Effect of dynamic exercise on left atrial function in conscious dogs. *J Physiol* 1994; **481 (Pt 2)**: 457-468 [PMID: 7738837 DOI: 10.1113/jphysiol.1994.sp020454]
97. **Tan YT**, Wenzelburger F, Lee E, Nightingale P, Heatlie G, Leyva F, Sanderson JE. Reduced left atrial function on exercise in patients with heart failure and normal ejection fraction. *Heart* 2010; **96**: 1017-1023 [PMID: 20584857 DOI: 10.1136/hrt.2009.189118]
98. **Pagel PS**, Kehl F, Gare M, Hettrick DA, Kersten JR, Warltier DC. Mechanical function of the left atrium: new insights based on analysis of pressure-volume relations and Doppler echocardiography. *Anesthesiology* 2003; **98**: 975-994 [PMID: 12657862 DOI: 10.1097/00000542-200304000-00027]
99. **Meris A**, Amigoni M, Uno H, Thune JJ, Verma A, Køber L, Bourgoun M, McMurray JJ, Velazquez EJ, Maggioni AP, Ghali J, Arnold JM, Zelenkofske S, Pfeffer MA, Solomon SD. Left atrial remodelling in patients with myocardial infarction complicated by heart failure, left ventricular dysfunction, or both: the VALIANT Echo study. *Eur Heart J* 2009; **30**: 56-65 [PMID: 19001474 DOI: 10.1093/eurheartj/ehn499]
100. **Ristow B**, Ali S, Whooley MA, Schiller NB. Usefulness of left atrial volume index to predict heart failure hospitalization and mortality in ambulatory patients with coronary heart disease and comparison to left ventricular ejection fraction (from the Heart and Soul Study). *Am J Cardiol* 2008; **102**: 70-76 [PMID: 18572038 DOI: 10.1016/j.amjcard.2008.02.099]

**P-Reviewer:** Teragawa H **S-Editor:** Kong JX **L-Editor: E-Editor:**

**Specialty type:** Medical laboratory technology

**Country of origin:** Australia

**Peer-review report classification**

Grade A (Excellent): A

Grade B (Very good): 0


Grade C (Good): 0

Grade D (Fair): 0



Grade E (Poor): 0


****

**Figure 1 Phases of left atrial function.** Left atrial preload is determined by blood flowing from the pulmonary vein. In this initial filling phase the LA acts a reservoir storing blood during left ventricular systole against a closed mitral valve. During LV diastole, diastasis and as the mitral valve opens it acts as a conduit, passively using stored energy to empty into the LV. Finally, in LV end diastole the LA contracts and actively empties blood completing the LV filling cycle. Reprinted from Karayannis *et al*[21], with permission of the publisher (Copyright © 2007, Springer Science + Business Media. Authorization for this adaptation has been obtained both from the owner of the copyright in the original work and from the owner of copyright in the translation or adaptation). LA: Left atrial; LV: Left ventricle; Vp: Left atrial volume before atrial contraction; Vmax: Maximal volume (as defined at left ventricular end-systolic phase); and Vmin: Left atrial minimal volume (as defined at left ventricular end-diastolic phase).

****

**Figure 2 Describes the volume and flow relationships in the left atrium and left ventricle throughout one cardiac cycle, *i.e.*, systole and diastole.** A: Pressure (P) and volume (V) are presented for the Aorta (Ao), left atrium (LA) and left ventricle (LV). Systole: During the early phase between mitral valve closure (mc) and aortic valve opening (ao) is the isovolumic contraction phase (stripped bar), where there is increase in PLV (solid line) without change in VLV (solid line). This is followed by ventricular contraction with a rise in PLV and PAO (upper dashed line), that peaks mid cycle, and a reduction in VLV. Diastole: At the end of LV contraction, and when the PLV is lower than the aorta the aortic valve closes (ac), followed by a period of isovolumic LV relaxation (stripped bar), where there is reduction in PLV without a change in VLV. The Incisura or dicrotic notch describes the small backflow of blood into the LV. Early diastolic point of early diastolic filling. In diastole PLA is generated early by the reservoir and conduit atrial function (v wave - lower dashed line) and corresponds with early diastolic filling (EDF) and a late atrial contraction or booster function (a wave) and contributes to late diastolic filling. Ventricular volumes are as end diastolic or end systolic (EDV or ESV; solid line). Cardiac sounds are shown as #1-#4; B: Diagram showing relationship between electrical conduction and blood flow with an additional catheter in the LV. Systolic blood flow out of the ventricle (V LV), is followed by early diastolic blood flow into the LV (E wave), bate blood flow into the LV during LA contraction (A wave). A standard ECG lead II shows LA depolarization, LV depolarization, and LV repolarization (P wave, QRS complex, and T wave, respectively) (Published in Ref 28, figure provided courtesy of Dr. John V. Tyberg and Dr. Henk E. D. J. ter Keurs. Permission required).

****

****

**Figure 3** **How to diagnose heart failure with preserved ejection fraction.** From the 2016 consensus statements of HF, the diagnosis of HF requires 4 important factors: (1) the presence of symptoms and/or signs of HF; (2) a “preserved” EF (defined as LVEF ≥ 50% or 40%-49% for HfmrEF; (3) elevated levels of natriuretic peptides (BNP > 35 pg/mL and/or NT-proBNP > 125 pg/mL); (4) objective evidence of other cardiac functional and structural alterations underlying HF; and (5) In case of uncertainty, a stress test or invasively measured elevated LV filling pressure may be needed to confirm the diagnosis. However in clinical practice many patients present predominately with a symptom such as SOB. The new guidelines are a positive step forward, and the authors for the first time acknowledged LA size, a surrogate for chronically elevated LVEDP and LA dysfunction. They fall short however as there are confounders for the abnormalities and none of the factors can be conclusively correlated to symptoms, where exercise testing could. A: Atrial filling velocity; BNP: Brain natriuretic peptides; E: Early filling velocity; e’: Early mitral annular tissue doppler velocity; EF: Ejection fraction; HfmrEF: Heart failure mid-range ejection fraction; LA: Left atrium; LAP: Left atrial pressure; LV: Left ventricle; LVEDP: Left ventricular end diastolic pressure; NT-proBNP: N Terminal Brain Natriuretic peptide; TR: Tricuspid regurgitation (adapted from References 1 and 3).

**Table 1 Imaging modalities and their correlations with components of atrial function1**

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| **LA function** | **Volumetric** | **Spectral Doppler** | | | **Tissue Doppler and**  **deformation indexes** | | |
| **LA volume fraction** | **Transmitral flow** | **PV flow** | **Composite indexes** | **TDI** | **Strain (ε)** | **Strain rate** |
| Global | LA EF [(LAmax - LAmin)/LAmax] | - | - | LAFI | - | - | - |
| Reservoir | Expansion index [(LAmax - LAmin)/LAmin] | - | S | - | S’ | S;  total | S |
| Conduit | Passive EF [(LAmax - LApre-A)/LAmax] | E  E/A | D | - | E’ | e-pos | E |
| Contractile (Booster) | Active EF [(LApre-A - LAmin)/LApre-A] | A  E/A  AFF | PVa | Ejection force (AEF)  LAKE | A’ | a-neg | A |

1Table modified from Ref[20,22]. ε: Strain; A/A’: Atrial contraction velocity/tissue Doppler velocity; AEF: Atrial ejection force Atrial ejection force = 0.5 × 1.06 g/cm3 × mitral annulus area (peak A velocity). Mass of blood is calculated as the product of the density of blood (ρ = 1.06 g/cm3) and volume of blood passing through mitral annulus; AFF: Atrial filling fraction, the ratio of the velocity time integral of the mitral A wave to the total diastolic transmitral flow; E/E’: Early diastole velocity/tissue Doppler velocity; EF: Emptying fraction; LA: Left atrial; LAEF: Left atrial emptying fraction; LAFI: Left atrial functional index; LAKE: Left atrial kinetic energy; LAmax: Maximum left atrial volume; LAmin: Minimum left atrial volume; neg: Negative; pos: Positive; preA: Preatrial contraction; PV: Pulmonary venous; Pva: Pulmonary venous reversal velocity; S/S’: Ventricular systole velocity/tissue Doppler velocity; TDI: Tissue Doppler imaging.